TRASTUZUMAB AND HYALURONIDASE-OYSK | B761106 | GENENTECH INC
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 12-Year BPCIA | Feb. 28, 2031 | Active | Computed |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 12331134(composition) · relevance 88/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
Top 50 of 243 AI-discovered patents by relevance.
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
The Trustees of the University of Pennsylvania v. Genentech, Inc. 2 patentstrastuzumab, pertuzumab | D. Del. | 2022-01-31 | Terminated 2025-03-14 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.